Angiopoietin concentrations in diabetic retinopathy
Authors:
Open Access
- 1 April 2005
- journal article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 89 (4) , 480-483
Abstract
Background/aim: Angiopoietin 1 and 2 interact with vascular endothelial growth factor (VEGF) to promote angiogenesis in animal and in vitro models. Although VEGF concentrations are elevated, there is little information regarding angiopoietin concentration in the vitreous of patients with diabetic retinopathy. Methods: Angiopoietin concentrations were measured by luminescence immunoassay in vitreous samples from 17 patients with non-proliferative diabetic retinopathy (NPDR) and clinically significant diabetic macular oedema (CSMO), 10 patients with proliferative diabetic retinopathy (PDR), and five patients with macular hole (controls) obtained at pars plana vitrectomy. Results: Angiopoietin 1 concentrations were low in patients with macular hole (median 17 pg/ml) while in NPDR with CSMO they were 2002 pg/ml (range 289–5820 pg/ml) and in PDR 186 pg/ml (range 26–2292 pg/ml). Angiopoietin 2 concentrations in NPDR with CSMO were a median of 4000 pg/ml (range 1341–14 329 pg/ml). For both macular hole and PDR patients angiopoietin 2 was below the limit of detection. Conclusions: Angiopoietin 2 concentration was twice that of angiopoietin 1 in NPDR with CSMO. Angiopoietin 2 is the natural antagonist of angiopoietin 1 which is thought to act as an anti-permeability agent. The predominance of angiopoietin 2 may allow VEGF induced retinal vascular permeability in patients with CSMO. The relatively low concentration of both angiopoietin 1 and 2 in patients with proliferative diabetic retinopathy may reflect the established nature of the neovascularisation in cases proceeding to vitrectomy.Keywords
This publication has 20 references indexed in Scilit:
- Suppression of Diabetic Retinopathy with Angiopoietin-1The American Journal of Pathology, 2002
- Biomedical significance of endothelial cell specific growth factor, angiopoietinExperimental & Molecular Medicine, 2002
- Angiopoietin-1 Is an Antipermeability and Anti-Inflammatory Agent In Vitro and Targets Cell JunctionsCirculation Research, 2000
- Leakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1Science, 1999
- Vascular Endothelial Growth Factor Induces Rapid Phosphorylation of Tight Junction Proteins Occludin and Zonula Occluden 1Journal of Biological Chemistry, 1999
- Breakdown of the Inner and Outer Blood Retinal Barrier in Streptozotocin-Induced DiabetesExperimental Eye Research, 1998
- Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia—Associated Iris Neovascularization in a Nonhuman PrimateArchives of Ophthalmology (1950), 1996
- Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formationNature, 1995
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994
- Loss of vision before ophthalmic referral in blind and partially sighted diabetics in Bristol.British Journal of Ophthalmology, 1994